Evidence map›Paper›PMID 39414986›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024

PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement.

Dean F Wong, Ganesh B Chand, Nicole Caito, Anna Eramo, Vincent T Grattan, Mark S Hixon, Ginger Nicol, Erin Lessie, Zachary Prensky, Hiroto Kuwabara and 5 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Dean F Wong *Mallinckrodt Institute of Radiology, and Department of Radiology, Washington University in Saint Louis, St. Louis, MO, USA. dfwong@wustl.edu.ORCID 0000-0001-9343-8367
Ganesh B ChandMallinckrodt Institute of Radiology, and Department of Radiology, Washington University in Saint Louis, St. Louis, MO, USA.
Nicole CaitoMallinckrodt Institute of Radiology, and Department of Radiology, Washington University in Saint Louis, St. Louis, MO, USA.
Anna EramoLB Pharmaceuticals Inc., New York, NY, USA.
Vincent T GrattanLB Pharmaceuticals Inc., New York, NY, USA.
Mark S HixonMark S. Hixon Consulting LLC, San Diego, CA, USA.
Ginger NicolDepartment of Psychiatry, Washington University in Saint Louis, St. Louis, MO, USA.ORCID 0000-0001-5823-6129
Erin LessieMallinckrodt Institute of Radiology, and Department of Radiology, Washington University in Saint Louis, St. Louis, MO, USA.
Zachary PrenskyLB Pharmaceuticals Inc., New York, NY, USA.
Hiroto KuwabaraJohns Hopkins University Department of Radiology, Baltimore, MD, USA.
Lucy TianMallinckrodt Institute of Radiology, and Department of Radiology, Washington University in Saint Louis, St. Louis, MO, USA.
Ines ValentaMallinckrodt Institute of Radiology, and Department of Radiology, Washington University in Saint Louis, St. Louis, MO, USA.
Thomas H SchindlerMallinckrodt Institute of Radiology, and Department of Radiology, Washington University in Saint Louis, St. Louis, MO, USA.
Gerhard GründerCentral Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Andrew R Vaino *LB Pharmaceuticals Inc., New York, NY, USA. andrew@lbpharma.us.ORCID 0000-0002-4159-0778

Funding

Characterizing Alzheimer's disease molecular and anatomical imaging markers and their relationships with cognition and genetics using machine learningK01AG083230 · NIA · WASHINGTON UNIVERSITY · PI Ganesh Chand · 2023 to 2026
$476k
NIA NIH HHS K01 AG083230
6 · The paper itself

Abstract

Regulation of dopamine activity has important clinical consequences, most notably in schizophrenia. LB-102, N-methyl amisulpride, is a novel dopamine D

Indexed as

Antipsychotic AgentsPositron-Emission TomographyAdultAmisulprideCorpus StriatumDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedRacloprideReceptors, Dopamine D2Young AdultAmisulprideAntipsychotic AgentsRacloprideReceptors, Dopamine D2

Identifiers

PMID39414986
PMCPMC11632090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.